[{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"0dede7b9-ee1b-410d-9416-c7e60518928b","acronym":"NSGO","url":"https://clinicaltrials.gov/study/NCT03267589","created_at":"2025-08-02T14:05:36.136Z","updated_at":"2025-08-02T14:05:36.136Z","phase":"Phase 2","brief_title":"Trial in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03267589 - NSGO","lead_sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","biomarkers":" CD73","pipe":"","alterations":" ","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2021","study_completion_date":" 10/19/2021","last_update_posted":"2025-07-29"},{"id":"1f0aec53-2934-4132-a061-58ff65518298","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984588","created_at":"2025-09-07T01:41:15.296Z","updated_at":"2025-09-07T01:41:15.296Z","phase":"Phase 2/3","brief_title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06984588","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 08/05/2028","primary_completion_date":" 08/05/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-05-22"},{"id":"3ec23c8c-cbf9-4200-8659-8f1562c5185d","acronym":"PACIFIC-9","url":"https://clinicaltrials.gov/study/NCT05221840","created_at":"2022-02-05T18:29:09.587Z","updated_at":"2025-02-25T16:38:50.332Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05221840 - PACIFIC-9","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 999","initiation":"Initiation: 02/07/2022","start_date":" 02/07/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-07"},{"id":"d8337ec5-4498-4bd7-8eca-3f7f9310b053","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431270","created_at":"2024-01-29T19:19:52.186Z","updated_at":"2025-02-25T17:25:40.711Z","phase":"Phase 1/2","brief_title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","source_id_and_acronym":"NCT05431270","lead_sponsor":"Phanes Therapeutics","biomarkers":" CD73","pipe":" | ","alterations":" PD-L1 expression","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • docetaxel • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-01-31"},{"id":"2c2514c9-d206-45c0-b6a6-81e2ea36d906","acronym":"Neo-CheckRay","url":"https://clinicaltrials.gov/study/NCT03875573","created_at":"2021-01-18T19:06:29.066Z","updated_at":"2025-02-25T15:08:26.710Z","phase":"Phase 2","brief_title":"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","source_id_and_acronym":"NCT03875573 - Neo-CheckRay","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • doxorubicin hydrochloride • cyclophosphamide • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2024-12-20"},{"id":"970c6f47-72fa-4370-9067-ddab6a5a704f","acronym":"SYNERGY","url":"https://clinicaltrials.gov/study/NCT03616886","created_at":"2021-01-18T17:46:20.617Z","updated_at":"2025-02-25T15:07:48.966Z","phase":"Phase 1/2","brief_title":"Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","source_id_and_acronym":"NCT03616886 - SYNERGY","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER • PGR • CD73","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"9455efaa-e977-4616-8644-72913019ad15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989387","created_at":"2021-08-04T13:52:52.724Z","updated_at":"2025-02-25T16:16:34.090Z","phase":"Phase 1","brief_title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04989387","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-11-06"},{"id":"ef8c69f2-9cbe-4385-a557-591f47dd7101","acronym":"","url":"https://clinicaltrials.gov/study/NCT03381274","created_at":"2021-01-18T16:41:08.185Z","updated_at":"2024-07-02T16:34:37.847Z","phase":"Phase 1/2","brief_title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","source_id_and_acronym":"NCT03381274","lead_sponsor":"MedImmune LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR T790M negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR T790M negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • oleclumab (MEDI9447) • imaradenant (AZD4635)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 05/08/2018","start_date":" 05/08/2018","primary_txt":" Primary completion: 05/24/2021","primary_completion_date":" 05/24/2021","study_txt":" Completion: 07/15/2025","study_completion_date":" 07/15/2025","last_update_posted":"2024-06-06"},{"id":"6bb1edff-f3e6-46a7-a9e0-e5a2bfe3f8ab","acronym":"EDGE-Gastric","url":"https://clinicaltrials.gov/study/NCT05329766","created_at":"2023-01-23T16:59:58.940Z","updated_at":"2024-07-02T16:34:38.031Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","source_id_and_acronym":"NCT05329766 - EDGE-Gastric","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-05"},{"id":"aa0bda28-21b1-44ee-bd83-6ab69706eeb9","acronym":"ARCHON-1","url":"https://clinicaltrials.gov/study/NCT03801902","created_at":"2021-01-18T18:47:37.181Z","updated_at":"2024-07-02T16:35:02.360Z","phase":"Phase 1","brief_title":"Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial","source_id_and_acronym":"NCT03801902 - ARCHON-1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"7f903bf7-9fc1-43cc-8ff0-c5b59af057ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04672434","created_at":"2021-01-19T20:44:53.857Z","updated_at":"2024-07-02T16:35:06.328Z","phase":"Phase 1","brief_title":"Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT04672434","lead_sponsor":"Symphogen A/S","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S95024 • Sym021"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/19/2020","start_date":" 11/19/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-02"},{"id":"18a1a3bc-cb86-4ec3-a940-d74393ef141c","acronym":"STAMINA-01","url":"https://clinicaltrials.gov/study/NCT05205109","created_at":"2024-02-20T18:31:22.397Z","updated_at":"2025-02-25T16:17:13.696Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05205109 - STAMINA-01","lead_sponsor":"Antengene Therapeutics Limited","biomarkers":" CD73","pipe":" | ","alterations":" CD73 expression","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2024-04-30"},{"id":"ab53141c-faa5-4818-bfa6-8bc2baf852f9","acronym":"DOSa","url":"https://clinicaltrials.gov/study/NCT04668300","created_at":"2024-04-15T18:24:09.850Z","updated_at":"2024-07-02T16:35:09.706Z","phase":"Phase 2","brief_title":"Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma","source_id_and_acronym":"NCT04668300 - DOSa","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • CD8 • PD-1 • CD73 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD73 expression","tags":["PD-L1 • CD8 • PD-1 • CD73 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-15"},{"id":"17124774-125f-48f3-9fa4-bdffab757f3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06300463","created_at":"2024-03-12T14:20:52.081Z","updated_at":"2024-07-02T16:35:09.965Z","phase":"Phase 2","brief_title":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT06300463","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-12"},{"id":"d9e41d11-6531-42e9-b1fb-7da01cc397b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454451","created_at":"2021-01-18T17:02:00.296Z","updated_at":"2024-07-02T16:35:25.568Z","phase":"Phase 1","brief_title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","source_id_and_acronym":"NCT03454451","lead_sponsor":"Corvus Pharmaceuticals, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 12/28/2022","primary_completion_date":" 12/28/2022","study_txt":" Completion: 02/19/2023","study_completion_date":" 02/19/2023","last_update_posted":"2023-12-21"},{"id":"81bc2bae-b93f-4add-aac2-cc81988be7aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056323","created_at":"2023-09-28T15:10:37.748Z","updated_at":"2024-07-02T16:35:32.257Z","phase":"Phase 1/2","brief_title":"A Study of HB0045 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06056323","lead_sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","biomarkers":" MSI • CD4","pipe":"","alterations":" ","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HB0045"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 09/19/2025","primary_completion_date":" 09/19/2025","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2023-10-20"},{"id":"f7269564-444d-4c70-92c1-a166c7275795","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001347","created_at":"2021-08-11T14:55:41.650Z","updated_at":"2024-07-02T16:35:33.668Z","phase":"Phase 2","brief_title":"A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors","source_id_and_acronym":"NCT05001347","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • uliledlimab (TJD5)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2023-10-12"},{"id":"e9745708-7929-4504-9e2d-4c705c19fc86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611556","created_at":"2023-10-04T01:11:28.511Z","updated_at":"2024-07-02T16:35:34.886Z","phase":"Phase 1b/2","brief_title":"MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.","source_id_and_acronym":"NCT03611556","lead_sponsor":"MedImmune LLC","biomarkers":" NT5E","pipe":" | ","alterations":" CD73 expression","tags":["NT5E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 07/22/2022","primary_completion_date":" 07/22/2022","study_txt":" Completion: 07/22/2022","study_completion_date":" 07/22/2022","last_update_posted":"2023-10-03"},{"id":"b306e56a-2d10-4caa-85ba-c58e65dbeea0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05944276","created_at":"2023-07-13T18:10:51.727Z","updated_at":"2024-07-02T16:35:43.117Z","phase":"Phase 1/2","brief_title":"A Study of HB0045 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05944276","lead_sponsor":"Huabo Biopharm Co., Ltd.","biomarkers":" MSI • CD4","pipe":"","alterations":" ","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HB0045"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 08/20/2023","start_date":" 08/20/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 03/19/2026","study_completion_date":" 03/19/2026","last_update_posted":"2023-07-13"},{"id":"e719e53a-348e-4f61-a2ec-8427efdc6994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846867","created_at":"2023-05-06T14:04:17.161Z","updated_at":"2024-07-02T16:35:48.741Z","phase":"Phase 1/2","brief_title":"Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients","source_id_and_acronym":"NCT05846867","lead_sponsor":"Akeso","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • MSH6 expression","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2023-05-08"},{"id":"cc0ff819-00f0-4f9d-9b06-d419790f5cbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04797468","created_at":"2022-10-26T18:06:23.272Z","updated_at":"2024-07-02T16:35:57.547Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor","source_id_and_acronym":"NCT04797468","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" CD68","pipe":"","alterations":" ","tags":["CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLX23"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/18/2022","start_date":" 07/18/2022","primary_txt":" Primary completion: 01/13/2023","primary_completion_date":" 01/13/2023","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-16"}]